While the Alzheimer’s disease care landscape is shifting, gaps to widespread therapeutic availability and imaging remain, said experts at AAIC 2026.

The post AAIC26: Alzheimer’s disease heterogeneity calls for a rethink appeared first on Clinical Trials Arena.